Infliximab to Treat Chronic Noninfectious Uveitis in Children: Retrospective Case Series with Long-term Follow-up

Ardoin, Stacy P.; Kredich, Deborah W.; Rabinovich, Egla; Schanberg, Laura E.; Jaffe, Glenn J.

doi:10.1016/j.ajo.2007.08.018

Cited by 104 publications

(65 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topical steroids were discontinued in 69%, and 58% remained free of uveitis recurrence at 1 year without any reported adverse event. 73 One study looking into the safety of Infliximab in the treatment of JIA included 348 patients, where 214 were on treatment with Infliximab. The most commonly observed adverse events included mild infections, infusion or injection site reactions and alanine aminotransferase elevations.…”

Section: Infliximabmentioning

confidence: 99%

Managing juvenile idiopathic arthritis–associated uveitis

Hawkins

Dick

Lee

et al. 2016

Survey of Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Infliximabmentioning

confidence: 99%

Managing juvenile idiopathic arthritis–associated uveitis

Hawkins

Dick

Lee

et al. 2016

Survey of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Regarding ADA, 20 of 25 children obtained remission over a median time of 12 weeks (range 2-12 weeks), with a median followup of 32 weeks (range 4 -40 weeks) (8,9,19,22) children receiving ADA (8,9,11,19,22), and 96 of 114 children receiving INF (8,9,12,13,17,18,21,(23)(24)(25)27,28). According to extractable data from 17 of 23 articles, discontinuation/tapering of concomitant DMARD therapy was possible for 4 of 22 children receiving ETA (29,30), 8 of 12 children receiving ADA (11,22), and 25 of 41 children receiving INF in addition to DMARDs (13,17,18,20,21,(23)(24)(25)27).…”

mentioning

confidence: 99%

Current Evidence of Anti–Tumor Necrosis Factor α Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta‐Analysis Approach of Individual Drugs

Simonini

Druce

Cimaz

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To summarize evidence regarding the effectiveness of anti-tumor necrosis factor ␣ (anti-TNF␣) treatments in childhood autoimmune chronic uveitis (ACU), refractory to previous disease-modifying antirheumatic drugs (DMARDs). Methods. A systematic search between January 2000 and October 2012 was conducted using EMBase, Ovid Medline, Evidence-Based Medicine (EBM) Reviews: American College of Physicians Journal Club, Cochrane libraries, and EBM Reviews. Studies investigating the efficacy of anti-TNF␣ therapy, in children ages <16 years, as the first treatment with a biologic agent for ACU, refractory to topical and/or systemic steroid therapy and at least 1 DMARD, were eligible for inclusion. The primary outcome measure was the improvement of intraocular inflammation, as defined by the Standardization of Uveitis Nomenclature Working Group criteria. We determined a combined estimate of the proportion of children responding to anti-TNF␣ treatment, including etanercept (ETA), infliximab (INF), or adalimumab (ADA). Results. We initially identified 989 articles, of which 148 were potentially eligible. In total, 22 retrospective chart reviews and 1 randomized clinical trial were deemed eligible, thus including 229 children (ADA: n ‫؍‬ 31, ETA: n ‫؍‬ 54, and INF: n ‫؍‬ 144). On pooled analysis of observational studies, the proportion of responding children was 87% (95% confidence interval [95% CI] 75-98%) for ADA, 72% (95% CI 64 -79%) for INF, and 33% (95% CI 19 -47%) for ETA. There was no difference in the proportion of responders between ADA and INF ( 2 ‫؍‬ 3.06, P ‫؍‬ 0.08), although both showed superior efficacy compared with ETA (ADA versus ETA: 2 ‫؍‬ 20.9, P < 0.001 and INF versus ETA: 2 ‫؍‬ 20.9, P < 0.001). Conclusion. Although randomized controlled trials are needed, the available evidence suggests that INF and ADA provide proven similar benefits in the treatment of childhood ACU, and they are both superior to ETA.

show abstract

“…To date, no studies have analyzed the value of cytokine blockade in the treatment of intraocular infection, but studies do describe the use of anti-TNFα drugs in treating intraocular inflammation during uveitis. [12][13][14] Our preliminary results demonstrate that TNFα blocking, even in the early stages of infection, may not improve the outcome of inflammation or infection. This is not surprising considering our findings of the production of additional chemotactic cytokines in the eye during experimental endophthalmitis in the mouse.…”

Section: Experiments 5: Analysis Of the Efficacy Of Anti-tnfα In Conjumentioning

confidence: 89%

Improved Therapeutic Regimens for Treatment of Post-Traumatic Ocular Infections

Callegan¹

2009

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

show abstract

Infliximab to Treat Chronic Noninfectious Uveitis in Children: Retrospective Case Series with Long-term Follow-up

Cited by 104 publications

References 20 publications

Managing juvenile idiopathic arthritis–associated uveitis

Managing juvenile idiopathic arthritis–associated uveitis

Current Evidence of Anti–Tumor Necrosis Factor α Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta‐Analysis Approach of Individual Drugs

Improved Therapeutic Regimens for Treatment of Post-Traumatic Ocular Infections

Contact Info

Product

Resources

About